| Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónica JAG Marco, PG Castellano, JL Jiménez, ER Herranz, JLS Moral, ... Medicina Clínica 141 (4), 175. e1-175. e8, 2013 | 16 | 2013 |
| National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ ola de Hematologı´ ay Hemoterapia and Grupo Espan˜ ol de Leucemia Linfocı … GM JA, SM JL, TC MJ Medicina Clinica 141 (4), 175. e1-8, 2013 | 5 | 2013 |
| Prognostic impact of the new CLL-IPI Index in a single center CLL Spanish cohort BF Lores, BN Cubells, AS Alcala, IC Martin, AT Casasus, SB Martinez, ... Blood 128 (22), 2019, 2016 | 3 | 2016 |
| Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study J Bravo, P Baltasar Tello, E González Garcia, E Ríos Herranz, AR Páyer, ... Leukemia & Lymphoma 64 (5), 913-926, 2023 | 1 | 2023 |
| Response-adapted treatment with rituximab/bendamustine/mitoxantrone/dexamethasone and maintenance therapy with rituximab in patients with follicular lymphoma in relapse or … FJ Peñalver Párraga, JA Márquez Navarro, S Durán Nieto, ... Blood, The Journal of the American Society of Hematology 128 (22), 1788-1788, 2016 | 1 | 2016 |
| Afiliación ÁM Pérez, ÁR Payer, JÁH Rivas, JL Pueyo, J de la Serna, RA Lapiedra, ... | 1 | 2010 |
| Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma … MG Mei, G Corazzelli, F Morschhauser, E Phillips, GP Collins, HJ Lee, ... Blood 142, 4433, 2023 | | 2023 |
| Digital PCR Assay for Evaluation of CD19-CAR-T Cells In Vivo Expansion in Aggressive B-Cell Lymphoma: Impact on Clinical Outcome L Ventura, A Serrano, BF Lores, R Hernani, ARV Tudorache, AI Teruel, ... Blood 142, 7153, 2023 | | 2023 |
| CD8+ T-cell exhaustion induced by leukemic cells mediates progression in chronic lymphocytic leukemia (CLL) I Jimenez, B Tazon-Vega, P Abrisqueta, JC Nieto, S Bobillo, C Palacio, ... LEUKEMIA & LYMPHOMA 61, 183-184, 2020 | | 2020 |
| VALIDATION STUDY OF THE TP53 GENE MUTATION ANALYSIS THROUGH MASSIVE SEQUENCING TECHNIQUES A Serrano Alcala, B Navarro Cubells, B Tazon Vega, F Bosch Albareda, ... HAEMATOLOGICA 104, 284-284, 2019 | | 2019 |
| A PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF OBINUTUZUMAB BENDAMUSTINE TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA J García‐Marco, P Baltasar Tello, E Gonzalez Garcia, E Ríos Herranz, ... Hematological Oncology 37, 380-382, 2019 | | 2019 |
| EFFICACY OF IBRUTINIB IN THE TREATMENT OF LINFOPROLIFERATIVE SYNDROMES: EXPERIENCE IN REAL LIFE OF THE VALENCIAN COMMUNITY EM Donato Martin, B Ferrer Lores, A Teruel Casasus, JA Blanco, ... HAEMATOLOGICA 103, 216-217, 2018 | | 2018 |
| PHASE II ASSAY TO EVALUATE THE EFFECTIVENESS OF OBINUTUZUMAB-BENDAMUSTINE COMBINATION IN PATIENTS WITH RECURRENT OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: GABRIELL STUDY JA Garcia Marco, P Baltasar Tello, E Gonzalez Garcia, E Rios Herranz, ... HAEMATOLOGICA 103, 63-64, 2018 | | 2018 |
| Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic … J Garcia-Marco, PB Tello, EG Garcia, ER Herranz, AR Payer, MJT Castera, ... Blood 130, 4321, 2017 | | 2017 |
| En nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC) ÁM Pérez, ÁR Payer, JÁH Rivas, JL Pueyo, J de la Serna Torroba, ... | | |
